

# Wiek H Van Gilst

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8602565/publications.pdf>

Version: 2024-02-01

411  
papers

32,459  
citations

4658

85  
h-index

5120

166  
g-index

423  
all docs

423  
docs citations

423  
times ranked

34023  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pectins from various sources inhibit galectin-3-related cardiac fibrosis. <i>Current Research in Translational Medicine</i> , 2022, 70, 103321.	1.8	2
2	Unravelling the Difference Between Men and Women in Post-CABG Survival. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 768972.	2.4	2
3	Age dependent associations of risk factors with heart failure: pooled population based cohort study. <i>BMJ, The</i> , 2021, 372, n461.	6.0	83
4	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. <i>Pflugers Archiv European Journal of Physiology</i> , 2021, 473, 1301-1313.	2.8	10
5	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 234-243.	1.8	10
6	Cardiac complications in patients hospitalised with COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 817-823.	1.0	108
7	Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study. <i>Journal of Hypertension</i> , 2020, 38, 1064-1071.	0.5	6
8	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
9	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiratorY dIstress syndrome in hospItAlized patIeNts with SARS-COV-2 Infection Disease. <i>American Heart Journal</i> , 2020, 226, 60-68.	2.7	12
10	The Cardiovascular Research community calls for action to address the growing burden of cardiovascular disease. <i>Cardiovascular Research</i> , 2019, 115, e96-e98.	3.8	17
11	Treating oxidative stress in heart failure: past, present and future. <i>European Journal of Heart Failure</i> , 2019, 21, 425-435.	7.1	407
12	Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 215.	6.1	186
13	Predictors and outcomes of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 651-659.	7.1	91
14	The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 701-709.	4.1	254
15	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017, 185, 140-149.	2.7	54
16	Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	89
17	Statin Effects on Metabolic Profiles. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	18
18	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	36

#	ARTICLE	IF	CITATIONS
19	In EXOG-depleted cardiomyocytes cell death is marked by a decreased mitochondrial reserve capacity of the electron transport chain. <i>BioEssays</i> , 2016, 38, S136-45.	2.5	5
20	Serial galectin-3 and future cardiovascular disease in the general population. <i>Heart</i> , 2016, 102, 1134-1141.	2.9	42
21	Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND. <i>International Journal of Cardiology</i> , 2016, 222, 385-390.	1.7	10
22	Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population-based cohort study. <i>ESC Heart Failure</i> , 2016, 3, 189-197.	3.1	25
23	In EXOG-depleted cardiomyocytes cell death is marked by a decreased mitochondrial reserve capacity of the electron transport chain. <i>Inside the Cell</i> , 2016, 1, 134-143.	0.4	0
24	52 Genetic Loci Influencing Myocardial Mass. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1435-1448.	2.8	113
25	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. <i>European Journal of Heart Failure</i> , 2016, 18, 814-821.	7.1	13
26	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. <i>Human Molecular Genetics</i> , 2016, 25, 2093-2103.	2.9	24
27	Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 97, 70-81.	1.9	15
28	Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. <i>Cardiovascular Research</i> , 2016, 111, 217-226.	3.8	24
29	Predicting Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	227
30	Emerging role of liver X receptors in cardiac pathophysiology and heart failure. <i>Basic Research in Cardiology</i> , 2016, 111, 3.	5.9	54
31	LXR± improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 634-643.	6.3	33
32	Cardiac LXR± protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. <i>EMBO Molecular Medicine</i> , 2015, 7, 1229-1243.	6.9	58
33	Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 699-707.	3.8	53
34	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 14</i> <i>Heart Journal</i> , 2015, 169, 693-701.e3.	2.7	16
35	Galectin-3, Renal Function, and Clinical Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2213-2221.	6.1	111
36	Telomere length and outcomes in ischaemic heart failure: data from the Controlled ROsuvastatin multiNATIONAL Trial in Heart Failure (CORONA). <i>European Journal of Heart Failure</i> , 2015, 17, 313-319.	7.1	19

#	ARTICLE	IF	CITATIONS
37	The liver X receptor agonist <sc>AZ876</sc> protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. <i>European Journal of Heart Failure</i> , 2015, 17, 273-282.	7.1	30
38	Sex differences in new-onset heart failure. <i>Clinical Research in Cardiology</i> , 2015, 104, 342-350.	3.3	89
39	Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. <i>Clinical Research in Cardiology</i> , 2015, 104, 812-821.	3.3	6
40	Long-term outcome in men and women after CABG; results from theÂIMAGINE trial. <i>Atherosclerosis</i> , 2015, 241, 284-288.	0.8	35
41	Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 131-140.	5.1	24
42	Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3151-3160.	6.1	20
43	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. <i>Nature Genetics</i> , 2015, 47, 1282-1293.	21.4	294
44	Î²-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 277-285.	2.6	12
45	Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1000-1007.	2.8	218
46	Hemoglobin levels and new-onset heart failure in the community. <i>American Heart Journal</i> , 2015, 169, 94-101.e2.	2.7	18
47	Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C155-C163.	4.6	19
48	Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2015, 385, 867-874.	13.7	47
49	Renal Handling of Galectinâ€³ in the General Population, Chronic Heart Failure, and Hemodialysis. <i>Journal of the American Heart Association</i> , 2014, 3, e000962.	3.7	46
50	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial <i>STXBP5</i> and <i>STX2</i>. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1093-1101.	2.4	43
51	Time of symptom onset and value of myocardial blush and infarct size on prognosis in patients with ST-elevation myocardial infarction. <i>Chronobiology International</i> , 2014, 31, 797-806.	2.0	9
52	Genetic Determinants of P Wave Duration and PR Segment. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 475-481.	5.1	45
53	The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COnTrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). <i>BMC Medical Genetics</i> , 2014, 15, 140.	2.1	9
54	Elevated urinary albumin excretion complements the Framingham Risk Score for the prediction of cardiovascular risk â€” response to treatment in the PREVENT IT trial. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 4, 193-197.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Telomere length loss due to smoking and metabolic traits. <i>Journal of Internal Medicine</i> , 2014, 275, 155-163.	6.0	151
56	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 314-320.	4.7	12
57	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 457-462.	3.9	60
58	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. <i>Circulation: Heart Failure</i> , 2014, 7, 723-731.	3.9	74
59	Cardiac Function and Architecture Are Maintained in a Model of Cardiorestricted Overexpression of the Prorenin-Renin Receptor. <i>PLoS ONE</i> , 2014, 9, e89929.	2.5	12
60	Abstract 19908: 5-oxoprolinase: a Novel Cardiac Mediator of the Oxidative Stress Response in the Failing Heart. <i>Circulation</i> , 2014, 130, .	1.6	0
61	Eindhoven dissertation prizes 2012. <i>Netherlands Heart Journal</i> , 2013, 21, 256-261.	0.8	3
62	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 433-439.	2.6	12
63	Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. <i>International Journal of Cardiology</i> , 2013, 169, 385-393.	1.7	14
64	Cyclical stretch induces structural changes in atrial myocytes. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 743-753.	3.6	33
65	The changing face of heart failure: are we really making progress?. <i>European Journal of Heart Failure</i> , 2013, 15, 960-962.	7.1	2
66	Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis. <i>Circulation: Heart Failure</i> , 2013, 6, 107-117.	3.9	371
67	Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. <i>Nature Genetics</i> , 2013, 45, 145-154.	21.4	675
68	Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial). <i>American Heart Journal</i> , 2013, 166, 357-364.e2.	2.7	95
69	Neurocardiology: close interaction between heart and brain. <i>Netherlands Heart Journal</i> , 2013, 21, 51-52.	0.8	42
70	Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia. <i>Cardiovascular Research</i> , 2013, 98, 37-46.	3.8	26
71	Identification of seven loci affecting mean telomere length and their association with disease. <i>Nature Genetics</i> , 2013, 45, 422-427.	21.4	808
72	Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. <i>Nature Genetics</i> , 2013, 45, 621-631.	21.4	282

#	ARTICLE	IF	CITATIONS
73	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1498-1506.	2.8	352
74	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. <i>European Heart Journal</i> , 2013, 34, 1424-1431.	2.2	451
75	Genome-Wide Association Study on Plasma Levels of Midregional-Proadrenomedullin and C-Terminal-Pro-Endothelin-1. <i>Hypertension</i> , 2013, 61, 602-608.	2.7	34
76	AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway. <i>International Journal of Molecular Sciences</i> , 2013, 14, 21378-21393.	4.1	17
77	AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes. <i>PLoS ONE</i> , 2013, 8, e80815.	2.5	18
78	A Simple and Computationally Efficient Approach to Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits. <i>PLoS ONE</i> , 2013, 8, e66545.	2.5	82
79	Atrial Remodeling Is Directly Related to End-Diastolic Left Ventricular Pressure in a Mouse Model of Ventricular Pressure Overload. <i>PLoS ONE</i> , 2013, 8, e72651.	2.5	41
80	Inflammation and anaemia in a broad spectrum of patients with heart failure. <i>Heart</i> , 2012, 98, 1237-1241.	2.9	22
81	Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. <i>Physiological Genomics</i> , 2012, 44, 443-454.	2.3	42
82	The <i>European Heart Journal</i> and the <i>European Journal of Heart Failure</i> : partners in scientific publishing. <i>European Journal of Heart Failure</i> , 2012, 14, 1075-1082.	7.1	6
83	The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 132, 282-289.	2.5	71
84	<i>DHRS7c</i> , a novel cardiomyocyte-expressed gene that is down-regulated by adrenergic stimulation and in heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 5-13.	7.1	24
85	Plasma renin and outcome in the community: data from PREVEND. <i>European Heart Journal</i> , 2012, 33, 2351-2359.	2.2	28
86	Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. <i>Blood</i> , 2012, 120, 4873-4881.	1.4	90
87	Seventy-five genetic loci influencing the human red blood cell. <i>Nature</i> , 2012, 492, 369-375.	27.8	320
88	Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. <i>Heart</i> , 2012, 98, 1348-1353.	2.9	27
89	Genome-wide meta-analysis of common variant differences between men and women. <i>Human Molecular Genetics</i> , 2012, 21, 4805-4815.	2.9	33
90	Association Between Chromosome 9p21 Variants and the Ankle-Brachial Index Identified by a Meta-Analysis of 21 Genome-Wide Association Studies. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 100-112.	5.1	98

#	ARTICLE	IF	CITATIONS
91	Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity. <i>PLoS ONE</i> , 2012, 7, e46781.	2.5	39
92	Comparing New Onset Heart Failure with Reduced Ejection Fraction and New Onset Heart Failure with Preserved Ejection Fraction: An Epidemiologic Perspective. <i>Current Heart Failure Reports</i> , 2012, 9, 363-368.	3.3	34
93	Eindhoven dissertation prizes 2011. <i>Netherlands Heart Journal</i> , 2012, 20, 240-244.	0.8	2
94	A Genome-Wide Association Study of Circulating Galectin-3. <i>PLoS ONE</i> , 2012, 7, e47385.	2.5	41
95	Animal models of cardiorenal syndrome: a review. <i>Heart Failure Reviews</i> , 2012, 17, 411-420.	3.9	31
96	Early mitral valve repair versus watchful waiting in patients with severe asymptomatic organic mitral regurgitation; rationale and design of the Dutch AMR trial, a multicenter, randomised trial. <i>Netherlands Heart Journal</i> , 2012, 20, 94-101.	0.8	20
97	The fibrosis marker galectin-3 and outcome in the general population. <i>Journal of Internal Medicine</i> , 2012, 272, 55-64.	6.0	303
98	Regulation of the (pro)renin-angiotensin receptor in cardiac remodelling. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 722-729.	3.6	23
99	Vitamin D status and outcomes in heart failure patients. <i>European Journal of Heart Failure</i> , 2011, 13, 619-625.	7.1	147
100	Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. <i>Nature</i> , 2011, 478, 103-109.	27.8	1,855
101	Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. <i>American Heart Journal</i> , 2011, 161, 1171-1178.	2.7	41
102	Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. <i>American Heart Journal</i> , 2011, 162, 487-493.	2.7	19
103	Telomere Length of Circulating Leukocyte Subpopulations and Buccal Cells in Patients with Ischemic Heart Failure and Their Offspring. <i>PLoS ONE</i> , 2011, 6, e23118.	2.5	41
104	Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review. <i>Current Drug Targets</i> , 2011, 12, 29-41.	2.1	55
105	Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. <i>Journal of Molecular Medicine</i> , 2011, 89, 377-387.	3.9	21
106	Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. <i>Cardiovascular Diabetology</i> , 2011, 10, 85.	6.8	101
107	Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. <i>European Journal of Heart Failure</i> , 2011, 13, 1275-1282.	7.1	70
108	Circulating Leukocyte and Carotid Atherosclerotic Plaque Telomere Length. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1219-1225.	2.4	40

#	ARTICLE	IF	CITATIONS
109	Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. <i>Human Molecular Genetics</i> , 2011, 20, 2273-2284.	2.9	168
110	Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. <i>Cardiovascular Research</i> , 2011, 89, 754-765.	3.8	220
111	Four Genetic Loci Influencing Electrocardiographic Indices of Left Ventricular Hypertrophy. Circulation: Cardiovascular Genetics, 2011, 4, 626-635.	5.1	28
112	Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial. <i>Heart</i> , 2011, 97, 1590-1596.	2.9	52
113	Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H459-H468.	3.2	144
114	The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-8.	1.1	19
115	Telomere biology in healthy aging and disease. <i>Pflugers Archiv European Journal of Physiology</i> , 2010, 459, 259-268.	2.8	216
116	Aging, telomeres and heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 479-486.	3.9	61
117	Activation of liver X receptor- $\beta$ reduces activation of the renal and cardiac renin-angiotensin-aldosterone system. <i>Laboratory Investigation</i> , 2010, 90, 630-636.	3.7	37
118	Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. <i>Nature Genetics</i> , 2010, 42, 1068-1076.	21.4	308
119	The emerging role of telomere biology in cardiovascular disease. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 35.	3.0	35
120	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. <i>Hypertension</i> , 2010, 56, 533-539.	2.7	25
121	A single dose of erythropoietin in ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 2593-2600.	2.2	144
122	Telomere length and outcome in heart failure. <i>Annals of Medicine</i> , 2010, 42, 36-44.	3.8	37
123	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. <i>Circulation</i> , 2010, 121, 52-62.	1.6	96
124	Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1407-1414.	2.4	211
125	Endogenous Erythropoietin and Outcome in Heart Failure. <i>Circulation</i> , 2010, 121, 245-251.	1.6	56
126	Telomere length and psychological well-being in patients with chronic heart failure. <i>Age and Ageing</i> , 2010, 39, 223-227.	1.6	50



#	ARTICLE	IF	CITATIONS
127	Circulating Rather Than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection After Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2010, 3, 286-293.	3.9	77
128	The <i>European Journal of Heart Failure</i> in 2010: current impact factor, time to first decision, and number of submissions. <i>European Journal of Heart Failure</i> , 2010, 12, 895-897.	7.1	3
129	Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy <i>in vivo</i> . <i>European Journal of Heart Failure</i> , 2010, 12, 1042-1050.	7.1	36
130	Bone marrow dysfunction in chronic heart failure patients. <i>European Journal of Heart Failure</i> , 2010, 12, 676-684.	7.1	86
131	Response to Letter Regarding Article, "Endogenous Erythropoietin and Outcome in Heart Failure". <i>Circulation</i> , 2010, 122, .	1.6	0
132	Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. <i>Cardiovascular Research</i> , 2010, 87, 30-39.	3.8	72
133	Left atrial pressure reduction for mitral stenosis reverses left atrial direction-dependent conduction abnormalities. <i>Cardiovascular Research</i> , 2010, 85, 711-718.	3.8	29
134	The (pro)renin receptor in health and disease. <i>Annals of Medicine</i> , 2010, 42, 13-18.	3.8	49
135	Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 348-353.	7.1	19
136	Erythropoiesis Stimulation in Acute Ischemic Syndromes. <i>Heart Failure Clinics</i> , 2010, 6, 313-321.	2.1	1
137	Qualitative examination of compliance in heart failure patients in The Netherlands. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2010, 39, 121-130.	1.6	80
138	Common variants near TERC are associated with mean telomere length. <i>Nature Genetics</i> , 2010, 42, 197-199.	21.4	296
139	ERYTHROPOIETIN RECEPTOR DEFICIENT MICE HAVE IMPAIRED CARDIAC ADAPTATION DURING VOLUNTARY EXERCISE. <i>Journal of the American College of Cardiology</i> , 2010, 55, A20.E191.	2.8	0
140	Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems. <i>PLoS ONE</i> , 2010, 5, e12757.	2.5	11
141	The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro. <i>PLoS ONE</i> , 2010, 5, e12963.	2.5	32
142	Ultrasound and Microbubble-Targeted Delivery of Macromolecules Is Regulated by Induction of Endocytosis and Pore Formation. <i>Circulation Research</i> , 2009, 104, 679-687.	4.5	388
143	Bradykinin Protects Against Oxidative Stress-Induced Endothelial Cell Senescence. <i>Hypertension</i> , 2009, 53, 417-422.	2.7	80
144	Proteinuria-Associated Endothelial Dysfunction Is Strain Dependent. <i>American Journal of Nephrology</i> , 2009, 30, 209-217.	3.1	13

#	ARTICLE	IF	CITATIONS
145	Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT <sub>1</sub> and epidermal growth factor receptor function. <i>European Journal of Heart Failure</i> , 2009, 11, 246-255.	7.1	13
146	Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor. <i>European Journal of Pharmacology</i> , 2009, 602, 373-379.	3.5	2
147	Renal dysfunction is associated with shorter telomere length in heart failure. <i>Clinical Research in Cardiology</i> , 2009, 98, 629-634.	3.3	33
148	Genome-wide association study identifies eight loci associated with blood pressure. <i>Nature Genetics</i> , 2009, 41, 666-676.	21.4	1,104
149	The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. <i>Clinical Science</i> , 2009, 116, 301-314.	4.3	33
150	Galectin-3: a novel mediator of heart failure development and progression. <i>European Journal of Heart Failure</i> , 2009, 11, 811-817.	7.1	434
151	Effects of Ivabradine and Metoprolol on Cardiac Angiogenesis and Endothelial Dysfunction in Rats With Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 9-17.	1.9	21
152	Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 265-274.	2.6	51
153	The case for statin therapy in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2008, 97, 139-146.	3.3	9
154	Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. <i>American Journal of Cardiology</i> , 2008, 102, 223-225.	1.6	5
155	Possible Association Between Telomere Length and Renal Dysfunction in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 207-210.	1.6	44
156	Erythropoietin in cardiac disease: New features of an old drug. <i>European Journal of Pharmacology</i> , 2008, 585, 270-277.	3.5	18
157	Caveolae and endothelial dysfunction: Filling the caves in cardiovascular disease. <i>European Journal of Pharmacology</i> , 2008, 585, 256-260.	3.5	42
158	Angiotensin-(1-7): Pharmacological properties and pharmacotherapeutic perspectives. <i>European Journal of Pharmacology</i> , 2008, 585, 303-312.	3.5	111
159	Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation. <i>International Journal of Cardiology</i> , 2008, 126, 209-215.	1.7	9
160	Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III). <i>American Heart Journal</i> , 2008, 155, 817-822.	2.7	52
161	Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. <i>Atherosclerosis</i> , 2008, 196, 349-355.	0.8	17
162	C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: Data from the prospective PREVEND cohort. <i>Atherosclerosis</i> , 2008, 196, 372-382.	0.8	38

#	ARTICLE	IF	CITATIONS
163	Non-Bone Marrow Origin of Neointimal Smooth Muscle Cells in Experimental In-Stent Restenosis in Rats. <i>Journal of Vascular Research</i> , 2008, 45, 493-502.	1.4	7
164	Nuclear Hormone Receptors as Regulators of the Renin-Angiotensin-Aldosterone System. <i>Hypertension</i> , 2008, 51, 1442-1448.	2.7	21
165	Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. <i>Coronary Artery Disease</i> , 2008, 19, 47-53.	0.7	13
166	Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study. <i>European Heart Journal</i> , 2008, 29, 673-679.	2.2	51
167	Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. <i>European Heart Journal</i> , 2008, 29, 1510-1515.	2.2	72
168	Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 1854-1860.	0.7	16
169	Effect of Moderate or Intensive Disease Management Program on Outcome in Patients With Heart Failure<sub>title>&#x27E6;Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH)&#x27E7;. <i>Archives of Internal Medicine</i> , 2008, 168, 316.	3.8	443
170	Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. <i>European Journal of Heart Failure</i> , 2008, 10, 22-29.	7.1	72
171	Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery. <i>Circulation</i> , 2008, 117, 24-31.	1.6	141
172	Genetic Architecture of Tissue-Type Plasminogen Activator and Plasminogen Activator Inhibitor-1. <i>Seminars in Thrombosis and Hemostasis</i> , 2008, 34, 562-568.	2.7	13
173	Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing. <i>Cardiovascular Research</i> , 2008, 81, 244-252.	3.8	70
174	Anemia in chronic heart failure: etiology and treatment options. <i>Current Opinion in Cardiology</i> , 2008, 23, 141-147.	1.8	25
175	Anemia and erythropoietin in heart failure. <i>Heart Failure Monitor</i> , 2008, 6, 28-33.	0.7	6
176	Acetylcholine stimulated dilatation and stretch induced myogenic constriction in mesenteric artery of rats with chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 144-151.	7.1	11
177	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. <i>European Heart Journal</i> , 2007, 28, 2018-2027.	2.2	210
178	Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 177-180.	1.7	5
179	Angiotensin II Type 2 Receptor Vasoactivity in Internal Mammary Arteries of Patients With Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 372-379.	1.9	11
180	Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most. <i>Current Opinion in Cardiology</i> , 2007, 22, 267-272.	1.8	13

#	ARTICLE	IF	CITATIONS
181	Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. <i>Genomics</i> , 2007, 89, 362-369.	2.9	30
182	A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart. <i>Cardiovascular Pathology</i> , 2007, 16, 127-135.	1.6	16
183	Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. <i>Life Sciences</i> , 2007, 80, 1678-1685.	4.3	25
184	Unraveling the mechanisms for heart failure patients' beliefs about compliance. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2007, 36, 253-261.	1.6	47
185	Optimization of ultrasound and microbubbles targeted gene delivery to cultured primary endothelial cells. <i>Journal of Drug Targeting</i> , 2007, 15, 664-671.	4.4	62
186	Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1459-1464.	2.8	257
187	Can Critically Short Telomeres Cause Functional Exhaustion of Progenitor Cells in Postinfarction Heart Failure?. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1911-1912.	2.8	14
188	Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 96-103.	1.9	20
189	Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 313-320.	3.8	44
190	Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study. <i>BMC Cardiovascular Disorders</i> , 2007, 7, 19.	1.7	3
191	Effect of Withdrawal of Pravastatin Therapy on C-Reactive Protein and Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2007, 100, 1548-1551.	1.6	18
192	Erythropoietin in Chronic Heart Failure. <i>Congestive Heart Failure</i> , 2007, 13, 289-292.	2.0	11
193	Renal Function Dependent Association of AGTR1 Polymorphism (A1166C) and Electrocardiographic Left-Ventricular Hypertrophy. <i>American Journal of Hypertension</i> , 2007, 20, 1097-1103.	2.0	18
194	The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context. <i>Human Genetics</i> , 2007, 122, 275-281.	3.8	16
195	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. <i>Current Heart Failure Reports</i> , 2007, 4, 127-133.	3.3	9
196	Protective Effects of Erythropoietin in Cardiac Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2161-2167.	2.8	167
197	Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function. <i>American Heart Journal</i> , 2006, 151, 1240-1246.	2.7	8
198	Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). <i>Clinical Therapeutics</i> , 2006, 28, 432-444.	2.5	113

#	ARTICLE	IF	CITATIONS
199	Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. <i>International Journal of Cardiology</i> , 2006, 106, 367-372.	1.7	120
200	EPO-induced neovascularization in heart failure rats. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 948.	1.9	0
201	A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study. <i>BMC Medical Genetics</i> , 2006, 7, 39.	2.1	39
202	The Current Role of ACE-inhibitors for Secondary Prevention in Cardiovascular Disease; from Pathogenesis to Clinical Practice. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 69-73.	2.6	10
203	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 135-141.	2.6	176
204	Usefulness of Preoperative C-Reactive Protein and Soluble Intercellular Adhesion Molecule-1 Level for Predicting Future Cardiovascular Events After Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 1697-1701.	1.6	19
205	Effects of C-Reactive Protein and Cholesterol on Responsiveness In Vitro of the Internal Thoracic Artery to Angiotensin II in Patients Having Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 98, 751-753.	1.6	8
206	Letter Regarding Article by Arnlov et al, "Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals". <i>Circulation</i> , 2006, 113, e406-e407.	1.6	0
207	The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3106-3114.	0.7	93
208	The relevance of comorbidities for heart failure treatment in primary care: A European survey. <i>European Journal of Heart Failure</i> , 2006, 8, 31-37.	7.1	26
209	Statins in the Treatment of Chronic Heart Failure: A Systematic Review. <i>PLoS Medicine</i> , 2006, 3, e333.	8.4	44
210	Statins in the treatment of chronic heart failure: Biological and clinical considerations. <i>Cardiovascular Research</i> , 2006, 71, 443-454.	3.8	44
211	Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction. <i>European Journal of Heart Failure</i> , 2006, 8, 122-130.	7.1	8
212	Compliance in heart failure patients: the importance of knowledge and beliefs. <i>European Heart Journal</i> , 2006, 27, 434-440.	2.2	433
213	Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 379-384.	2.4	20
214	Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. <i>European Heart Journal</i> , 2006, 28, 166-171.	2.2	134
215	Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. <i>Hypertension</i> , 2006, 48, 870-876.	2.7	16
216	The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. <i>Thrombosis and Haemostasis</i> , 2006, 96, 471-477.	3.4	33

#	ARTICLE	IF	CITATIONS
217	Letter Regarding Article by Arnlov et al, "Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals". <i>Circulation</i> , 2006, 113, .	1.6	1
218	The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. <i>Thrombosis and Haemostasis</i> , 2006, 96, 471-7.	3.4	20
219	Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 88-98.	1.9	18
220	Left Ventricular Assessment in Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2005, 165, 2162.	3.8	18
221	Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: Differential effects on lisinopril and zofenopril. <i>European Journal of Pharmacology</i> , 2005, 527, 141-149.	3.5	11
222	Effect of Intensive Versus Moderate Lipid Lowering on Endothelial Function and Vascular Responsiveness to Angiotensin II in Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 1361-1364.	1.6	39
223	Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 129, 330-335.	0.8	47
224	Heart failure guidelines and prescribing in primary care across Europe. <i>BMC Health Services Research</i> , 2005, 5, 57.	2.2	12
225	Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. <i>Vascular Pharmacology</i> , 2005, 42, 125-140.	2.1	37
226	Acute Administration of Angiotensin Converting Enzyme Inhibitors in Thrombolysed Myocardial Infarction Patients Is Associated with a Decreased Incidence of Heart Failure, but an Increased Re-Infarction Risk. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 119-124.	2.6	9
227	Statins and Autonomic Function in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 167-168.	2.6	3
228	Erythropoietin: From Hematopoiesis to Cardioprotection. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 7-8.	2.6	8
229	Beneficial effects of add-on hydrochlorothiazide in rats with myocardial infarction optimally treated with quinapril. <i>European Journal of Heart Failure</i> , 2005, 7, 1085-1094.	7.1	4
230	Angiotensin-(1-7) Attenuates Neointimal Formation After Stent Implantation in the Rat. <i>Hypertension</i> , 2005, 45, 138-141.	2.7	96
231	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3391-3399.	1.6	101
232	Letters to the Editor. <i>Hypertension</i> , 2005, 46, e20.	2.7	1
233	High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, 145-150.	1.7	5
234	Levels of Hematopoiesis Inhibitor N <sup>1</sup> -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. <i>Circulation</i> , 2005, 112, 1743-1747.	1.6	120

#	ARTICLE	IF	CITATIONS
235	Improvement of EDHF by Chronic ACE Inhibition Declines Rapidly After Withdrawal in Rats With Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 46, 766-772.	1.9	8
236	Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria. <i>Stroke</i> , 2005, 36, 649-653.	2.0	44
237	Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVENT Intervention Trial. <i>European Heart Journal</i> , 2005, 26, 1314-1320.	2.2	51
238	Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?The opinions expressed in this article are not necessarily those of the Editors of the <i>European Heart Journal</i> or of the <i>European Society of Cardiology</i> .. <i>European Heart Journal</i> , 2005, 26, 2361-2367.	2.2	31
239	C-reactive protein and microalbuminuria are associated with atrial fibrillation. <i>International Journal of Cardiology</i> , 2005, 98, 73-77.	1.7	80
240	Pre-procedural ACE-activity does not predict symptomatic in-stent restenosis. <i>International Journal of Cardiology</i> , 2005, 103, 73-77.	1.7	0
241	Determination of vessel size: a putative framework to assess clinical outcome. <i>International Journal of Cardiology</i> , 2005, 103, 135-139.	1.7	4
242	Hemoglobin levels and 30-day mortality in patients after myocardial infarction. <i>International Journal of Cardiology</i> , 2005, 100, 289-292.	1.7	70
243	Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 125-133.	2.8	232
244	Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. <i>American Journal of Hypertension</i> , 2005, 18, 342-347.	2.0	35
245	High Prevalence of Microalbuminuria in Chronic Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2005, 11, 602-606.	1.7	48
246	A simple, inexpensive, rapid, and accurate preclinical model for in-stent restenosis. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1310.	2.8	2
247	Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 130-134.	1.7	15
248	Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 27-32.	1.7	10
249	Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria. <i>Circulation</i> , 2004, 110, 2809-2816.	1.6	489
250	Rat Abdominal Aorta Stenting: A New and Reliable Small Animal Model for In-Stent Restenosis. <i>Journal of Vascular Research</i> , 2004, 41, 377-386.	1.4	43
251	Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 161-168.	1.7	3
252	Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting. <i>Hypertension</i> , 2004, 44, 930-934.	2.7	15

#	ARTICLE	IF	CITATIONS
253	Erythropoietin in cardiovascular diseases. <i>European Heart Journal</i> , 2004, 25, 285-291.	2.2	136
254	Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 473-479.	1.9	152
255	Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. <i>European Journal of Heart Failure</i> , 2004, 6, 853-859.	7.1	92
256	Framingham score and microalbuminuria: Combined future targets for primary prevention?. <i>Kidney International</i> , 2004, 66, S111-S114.	5.2	25
257	Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram. <i>American Journal of Cardiology</i> , 2004, 94, 1063-1067.	1.6	9
258	Sertraline Causes Strong Coronary Vasodilation: Possible Relevance for Cardioprotection by Selective Serotonin Reuptake Inhibitors. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 441-447.	2.6	19
259	New Pharmacological Strategies in Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 491-501.	2.6	4
260	Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. <i>Journal of Molecular Medicine</i> , 2004, 82, 678-687.	3.9	55
261	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004, 25, 1911-1919.	2.2	126
262	Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 63-67.	2.8	178
263	Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 137-142.	1.9	4
264	Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria?. <i>International Journal of Cardiology</i> , 2004, 93, 211-215.	1.7	58
265	The role of coronary endothelial function testing in patients suspected for angina pectoris. <i>International Journal of Cardiology</i> , 2004, 96, 123-129.	1.7	10
266	Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II. <i>Journal of Hypertension</i> , 2004, 22, 2355-2361.	0.5	29
267	Coronary vasomotor response is related to the angiographic extent of coronary sclerosis in patients with stable angina pectoris. <i>Clinical Science</i> , 2004, 106, 115-120.	4.3	8
268	Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 38.	7.4	0
269	Long Term Angiotensin Converting Enzyme-inhibition in Patients after Coronary Artery Bypass Grafting Reduces Levels of Soluble Intercellular Cell Adhesion Molecule-1. <i>European Journal of Vascular and Endovascular Surgery</i> , 2003, 26, 387-391.	1.5	15
270	Relation of electrocardiographic abnormalities to levels of serum C-reactive protein. <i>American Journal of Cardiology</i> , 2003, 91, 1358-1360.	1.6	5



#	ARTICLE	IF	CITATIONS
271	Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000. <i>Pharmacoepidemiology and Drug Safety</i> , 2003, 12, 327-334.	1.9	15
272	Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT <sub>1</sub> receptor blockade. <i>British Journal of Pharmacology</i> , 2003, 139, 1317-1325.	5.4	43
273	Specific MAP-Kinase Blockade Protects against Renal Damage in Homozygous TGR(mRen2)27 Rats. <i>Laboratory Investigation</i> , 2003, 83, 1761-1770.	3.7	28
274	The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe Part 2: treatment. <i>European Heart Journal</i> , 2003, 24, 464-474.	2.2	711
275	The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. <i>European Heart Journal</i> , 2003, 24, 442-463.	2.2	1,154
276	The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice. <i>European Journal of Heart Failure</i> , 2003, 5, 187-193.	7.1	9
277	Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 147-154.	7.1	21
278	Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries. <i>Cardiovascular Research</i> , 2003, 59, 980-987.	3.8	6
279	Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. <i>European Heart Journal</i> , 2003, 24, 412-420.	2.2	144
280	Increased expression of cardiac angiotensin II type 1 (AT) receptors decreases myocardial microvessel density after experimental myocardial infarction. <i>Cardiovascular Research</i> , 2003, 57, 434-442.	3.8	52
281	The pharmacological management of heart failure: too many treatments?. <i>European Journal of Heart Failure</i> , 2003, 5, 5-8.	7.1	5
282	Differences Between Angiotensin-Converting Enzyme Inhibition and Angiotensin II-AT1 Antagonism on Angiotensin-Mediated Responses in Human Internal Mammary Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2003, 41, 178-184.	1.9	9
283	Exercise-Induced Ischemia after Successful Percutaneous Coronary Intervention Is Related to Distal Coronary Endothelial Dysfunction. <i>Journal of Investigative Medicine</i> , 2003, 51, 221.	1.6	4
284	Difference in the Relation Between Urinary Albumin Excretion and Carotid Intima-Media Thickness in Nondiabetic and Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2002, 25, 936-937.	8.6	13
285	Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. <i>European Heart Journal</i> , 2002, 23, 536-542.	2.2	26
286	N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts. <i>Hypertension</i> , 2002, 40, 155-161.	2.7	58
287	Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. <i>Circulation</i> , 2002, 106, 1777-1782.	1.6	1,395
288	Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. <i>Cardiovascular Research</i> , 2002, 54, 380-389.	3.8	124

#	ARTICLE	IF	CITATIONS
289	Efficacy of Angiotensin II Type 1 Receptor Blockade on Reperfusion-Induced Arrhythmias and Mortality Early After Myocardial Infarction Is Increased in Transgenic Rats With Cardiac Angiotensin II Type 1 Overexpression. <i>Journal of Cardiovascular Pharmacology</i> , 2002, 39, 610-619.	1.9	14
290	Angiotensin-(1 $\alpha$ 7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats. <i>Circulation</i> , 2002, 105, 1548-1550.	1.6	299
291	Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1401-1407.	2.8	45
292	Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. <i>Atherosclerosis</i> , 2002, 163, 121-126.	0.8	44
293	Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. <i>Lancet, The</i> , 2002, 360, 1631-1639.	13.7	493
294	Thoroscopic monitoring for pericardial application of local drug or gene therapy. <i>International Journal of Cardiology</i> , 2002, 82, 117-121.	1.7	13
295	Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model. <i>European Journal of Heart Failure</i> , 2002, 4, 277-282.	7.1	0
296	Endothelial Dysfunction in Patients with Coronary Artery Disease: A Comparison of Three Frequently Reported Tests. <i>Journal of Investigative Medicine</i> , 2002, 50, 19-24.	1.6	37
297	Rat abdominal aortic stenting: a simple model displaying in-stent restenosis. <i>American Journal of Cardiology</i> , 2002, 89, 1149-1150.	1.6	10
298	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. <i>Kidney International</i> , 2002, 62, 181-191.	5.2	37
299	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 149-160.	2.6	118
300	Functional antagonism of different angiotensin II type I receptor blockers in human arteries. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 311-316.	2.6	9
301	Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale. <i>Canadian Journal of Cardiology</i> , 2002, 18, 1191-200.	1.7	15
302	Angiotensin receptors in the cardiovascular system. <i>Canadian Journal of Cardiology</i> , 2002, 18, 1331-9.	1.7	36
303	Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. <i>Journal of the American College of Cardiology</i> , 2001, 37, 470-474.	2.8	14
304	Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K <sup>+</sup> channels. <i>Journal of the American College of Cardiology</i> , 2001, 37, 926-932.	2.8	189
305	Early expression of natriuretic peptides and SERCA in mild heart failure. <i>International Journal of Cardiology</i> , 2001, 78, 5-12.	1.7	29
306	Endothelin System in Human Persistent and Paroxysmal Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 737-742.	1.7	45

#	ARTICLE	IF	CITATIONS
307	Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. <i>Journal of Internal Medicine</i> , 2001, 249, 519-526.	6.0	547
308	Effects of quinapril on clinical outcome after coronary artery bypass grafting (the QUO VADIS study). <i>American Journal of Cardiology</i> , 2001, 87, 542-546.	1.6	135
309	Relation between albumin in the urine and electrocardiographic markers of myocardial ischemia in patients without diabetes mellitus. <i>American Journal of Cardiology</i> , 2001, 88, 771-774.	1.6	11
310	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. <i>American Journal of Cardiology</i> , 2001, 88, 1-20.	1.6	202
311	Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, S64-S69.	1.7	4
312	Recommendations for exercise testing in chronic heart failure patients. <i>European Heart Journal</i> , 2001, 22, 37-45.	2.2	113
313	Ion Channel Remodeling Is Related to Intraoperative Atrial Effective Refractory Periods in Patients With Paroxysmal and Persistent Atrial Fibrillation. <i>Circulation</i> , 2001, 103, 684-690.	1.6	232
314	Beta-blocker titration failure is independent of severity of heart failure. <i>American Journal of Cardiology</i> , 2000, 85, 509-512.	1.6	12
315	Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the prevention of Renal and vascular Endstage disease intervention trial [PREVEND]). <i>TJ ETQq1 1 0.784314 18BT /OV</i>	1.6	65
316	Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators. <i>Cardiovascular Drugs and Therapy</i> , 2000, 14, 55-60.	2.6	23
317	Increased kallikrein expression protects against cardiac ischemia. <i>FASEB Journal</i> , 2000, 14, 1861-1863.	0.5	37
318	Vasopeptidase inhibition in heart failure. <i>Lancet, The</i> , 2000, 356, 1526.	13.7	4
319	Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. <i>Journal of the Autonomic Nervous System</i> , 2000, 78, 117-121.	1.9	10
320	Chronic beta-blocker treatment in patients with advanced heart failure. <i>International Journal of Cardiology</i> , 2000, 73, 7-12.	1.7	31
321	$\beta^2$ -Adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of $\beta^1$ -adrenoceptor density. <i>International Journal of Cardiology</i> , 2000, 72, 137-141.	1.7	29
322	Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2000, 355, 1751-1756.	13.7	85
323	Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries. <i>Hypertension</i> , 2000, 35, 717-721.	2.7	149
324	Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2047-2053.	2.8	27

#	ARTICLE	IF	CITATIONS
325	Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2000, 35, 19-28.	2.8	218
326	Direct Vasodilating Effects of the New Dopaminergic Agonist Z1046 in Human Arteries. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, 581-585.	1.9	5
327	Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. <i>European Journal of Heart Failure</i> , 1999, 1, 139-144.	7.1	39
328	Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. <i>Cardiovascular Research</i> , 1999, 42, 443-454.	3.8	152
329	Angiotensin-(1 $\alpha$ 7) Is a Modulator of the Human Renin-Angiotensin System. <i>Hypertension</i> , 1999, 34, 296-301.	2.7	164
330	The ACE gene polymorphism: the good, the bad and the ugly. <i>Cardiovascular Research</i> , 1999, 43, 23-24.	3.8	6
331	Gene Expression of the Natriuretic Peptide System in Atrial Tissue of Patients with Paroxysmal and Persistent Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 827-835.	1.7	54
332	Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour holter substudy of the cardiac insufficiency bisoprolol study [CIBIS]) <sup>11</sup> This study was sponsored by E. Merck, Darmstadt, Germany.. <i>American Journal of Cardiology</i> , 1999, 83, 1286-1289.	1.6	9
333	A comparison of the cold pressor test and the diving test on coronary and systemic hemodynamics in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 1999, 71, 7-15.	1.7	2
334	Dosing of ACE Inhibitors in Left Ventricular Dysfunction: Does Current Clinical Dosing Provide Optimal Benefit?. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 34, S13-S17.	1.9	3
335	Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and $\hat{I}^2$ -adrenergic neuroeffector mechanisms in transgenic (mREN2) <sup>27</sup> rats. <i>British Journal of Pharmacology</i> , 1998, 123, 405-412.	5.4	25
336	Dual pathway for angiotensin II formation in human internal mammary arteries. <i>British Journal of Pharmacology</i> , 1998, 125, 1028-1032.	5.4	62
337	Effects of Aspirin on Angiotensin-Converting Enzyme Inhibition and Left Ventricular Dilatation One Year After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1998, 81, 1178-1181.	1.6	57
338	Sample Dilution: A Methodological Pitfall in the Measurement of Tissue but not Serum Ace-Activity. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 39, 45-49.	0.7	9
339	Spinal cord stimulation in chronic intractable angina pectoris: A randomized, controlled efficacy study. <i>American Heart Journal</i> , 1998, 136, 1114-1120.	2.7	202
340	Long-term follow-up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina pectoris. <i>European Heart Journal</i> , 1998, 19, 1208-1213.	2.2	13
341	$\hat{I}^2$ -Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. <i>Cardiovascular Research</i> , 1998, 40, 146-155.	3.8	25
342	Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2) <sup>27</sup> transgenic hypertensive rats. <i>Journal of Hypertension</i> , 1998, 16, 1759-1765.	0.5	29

#	ARTICLE	IF	CITATIONS
343	Left Ventricular Dilatation After Myocardial Infarction: ACE Inhibitors, $\beta$ -Blockers, or Both?. Journal of Cardiovascular Pharmacology, 1998, 32, S1-S8.	1.9	7
344	Left Ventricular Dilatation After Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1998, 32, S1-S8.	1.9	9
345	Genetic factors in the progression of atherosclerosis and response to cholesterol lowering drugs. Developments in Cardiovascular Medicine, 1998, , 95-100.	0.1	0
346	Coronary Vascular Function in Stable and Unstable Angina. Developments in Cardiovascular Medicine, 1998, , 55-66.	0.1	0
347	Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus. Cardiovascular Research, 1997, 35, 498-504.	3.8	15
348	Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats. Journal of Cardiac Failure, 1997, 3, 199-205.	1.7	2
349	Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: effects of ibopamine and captopril. Journal of Cardiac Failure, 1997, 3, 125-132.	1.7	6
350	Long-Term Anti-Ischemic Effects of Angiotensin-Converting Enzyme Inhibition in Patients After Myocardial Infarction This study was presented in part at the 46th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 1997 and was supported by a grant from Bristol Meyers Squibb, Woerden, The Netherlands.. Journal of the American College of Cardiology, 1997, 30, 400-405.	2.8	40
351	Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. Cardiovascular Research, 1997, 34, 568-574.	3.8	14
352	Perfusion-Independent Effect of Bradykinin and Fosinoprilate on Glucose Transport in Langendorff Rat Hearts. American Journal of Cardiology, 1997, 80, 143A-147A.	1.6	17
353	Efficacy, Safety, and Determinants of Conversion of Atrial Fibrillation and Flutter With Oral Amiodarone. American Journal of Cardiology, 1997, 79, 53-57.	1.6	106
354	Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. Journal of Molecular Medicine, 1997, 75, 371-377.	3.9	46
355	Differential Inhibition of Plasma Versus Tissue ACE by Utibapril: Biochemical and Functional Evidence for Inhibition of Vascular ACE Activity. Journal of Cardiovascular Pharmacology, 1997, 29, 684-691.	1.9	22
356	Effects of Amlodipine on Endothelial Function in Rats with Chronic Heart Failure After Experimental Myocardial Infarction. Journal of Cardiovascular Pharmacology, 1997, 30, 683-689.	1.9	4
357	Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilatation After Myocardial Infarction. Circulation, 1997, 95, 2607-2609.	1.6	23
358	Myocardial Infarction with Aortic Banding. A Combined Rat Model of Heart Failure.. International Heart Journal, 1997, 38, 697-708.	0.6	4
359	Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS). Journal of the American College of Cardiology, 1996, 28, 114-121.	2.8	67
360	Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. International Journal of Cardiology, 1996, 53, 37-43.	1.7	5

#	ARTICLE	IF	CITATIONS
361	Safety of beta-blocker therapy with and without thrombolysis: a comparison of bisoprolol and atenolol in acute myocardial infarction. <i>Current Therapeutic Research</i> , 1996, 57, 313-326.	1.2	7
362	Left ventricular wall motion score as an early predictor of left ventricular dilation and mortality after first anterior infarction treated with thrombolysis. <i>American Journal of Cardiology</i> , 1996, 77, 1149-1154.	1.6	41
363	Activated tissue renin-angiotensin systems add to the progression of heart failure. <i>Basic Research in Cardiology</i> , 1996, 91, 85-90.	5.9	7
364	Relation between myocardial $\hat{A}$ -adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. <i>Cardiovascular Research</i> , 1995, 30, 386-393.	3.8	6
365	Hyperactive Tissue Renin-Angiotensin Systems in Cardiovascular Dysfunction: Experimental Evidence and Clinical Hypotheses. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 441-468.	1.3	15
366	Effects of Spirapril and Captopril on Regional Blood Flow in Chronic Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 105-112.	1.9	9
367	Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1622-1626.	2.8	103
368	Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. <i>Lancet, The</i> , 1995, 346, 1653-1657.	13.7	39
369	Association of Left Ventricular Remodeling and Nonuniform Electrical Recovery Expressed by Nondipolar QRST Integral Map Patterns in Survivors of a First Anterior Myocardial Infarction. <i>Circulation</i> , 1995, 92, 300-310.	1.6	30
370	Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1994, 8, 245-250.	2.6	11
371	Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: Patency and clinical outcome at 1 year. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1181-1188.	2.8	27
372	Left ventricular dilatation and high-grade ventricular arrhythmias in the first year after myocardial infarction. <i>Journal of Cardiac Failure</i> , 1994, 1, 3-11.	1.7	13
373	Late potentials, QTc prolongation, and prediction of arrhythmic events after myocardial infarction. <i>International Journal of Cardiology</i> , 1994, 46, 121-128.	1.7	8
374	Effect of Isradipine and Nifedipine on Diastolic Function in Patients with Left Ventricular Dysfunction Due to Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 952-958.	1.9	2
375	Effects of streptokinase during acute myocardial infarction on the signal-averaged electrocardiogram and on the frequency of late arrhythmias. <i>American Journal of Cardiology</i> , 1993, 72, 647-651.	1.6	12
376	Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure. <i>American Journal of Cardiology</i> , 1993, 71, 992-994.	1.6	14
377	The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. <i>Atherosclerosis</i> , 1993, 103, 221-230.	0.8	33
378	Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. <i>Lancet, The</i> , 1993, 342, 257-264.	13.7	109

#	ARTICLE	IF	CITATIONS
379	Spontaneous ventricular defibrillation.. Heart, 1993, 70, 590-591.	2.9	7
380	Protection of the Myocardium Against Postischemic Reperfusion Damage. Journal of Cardiovascular Pharmacology, 1992, 19, S13-S17.	1.9	5
381	The possible role of converting enzyme inhibition in acute myocardial infarction. Journal of Molecular and Cellular Cardiology, 1992, 24, S19.	1.9	0
382	Late Potentials in a Porcine Model of Anterior Wall Myocardial Infarction and Their Relation to Inducible Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 1760-1771.	1.2	3
383	Triggered activity as arrhythmogenic mechanism after myocardial infarction: Clinical and electrophysiologic study of one case. Clinical Cardiology, 1992, 15, 689-692.	1.8	4
384	Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. American Heart Journal, 1991, 121, 51-56.	2.7	56
385	The Acute Hemodynamic, Hormonal, and Pharmacokinetic Properties of Oral Spirapril in Patients with Moderate to Severe Heart Failure. Journal of Cardiovascular Pharmacology, 1991, 18, 614-621.	1.9	6
386	Converting Enzyme Inhibitors and the Role of the Sulfhydryl Group in the Potentiation of Exo- and Endogenous Nitrovasodilators. Journal of Cardiovascular Pharmacology, 1991, 18, 429-436.	1.9	46
387	Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation. American Journal of Cardiology, 1991, 67, 93-95.	1.6	52
388	Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in acute myocardial infarction: Rationale and design of captopril and thrombolysis study. American Journal of Cardiology, 1991, 68, 111-115.	1.6	8
389	Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. American Journal of Cardiology, 1991, 68, 41-46.	1.6	448
390	Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. American Journal of Cardiology, 1991, 68, 335-341.	1.6	250
391	Coronary vasodilation induced by captopril and zofenoprilat: evidence for a prostaglandin-independent mechanism. Naunyn-Schmiedeberg's Archives of Pharmacology, 1991, 343, 491-495.	3.0	8
392	Beneficial effects of bradykinin on porcine ischemic myocardium. Basic Research in Cardiology, 1991, 86, 107-116.	5.9	28
393	Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovascular Research, 1991, 25, 936-942.	3.8	23
394	Xamoterol in autonomic and intrinsic sinus node dysfunction. American Journal of Cardiology, 1990, 65, 814-816.	1.6	2
395	The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovascular Drugs and Therapy, 1990, 4, 695-703.	2.6	30
396	The effects off bradykinin on the isolated rat heart. European Journal of Pharmacology, 1990, 183, 2227.	3.5	1

#	ARTICLE	IF	CITATIONS
397	Flecainide Versus Quinidine in the Prevention of Paroxysms of Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 13, 32.	1.9	61
398	Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. <i>American Journal of Cardiology</i> , 1989, 64, 1317-1321.	1.6	183
399	Effects of flecainide on the atrial defibrillation threshold. <i>American Journal of Cardiology</i> , 1989, 63, 112-114.	1.6	56
400	Flecainide acetate in the treatment of supraventricular tachycardias: Value of programmed electrical stimulation for long-term prognosis. <i>American Heart Journal</i> , 1989, 117, 365-369.	2.7	12
401	The haemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin. <i>Journal of Hypertension</i> , 1989, 7, S296-297.	0.5	4
402	Effects of Angiotensin II and Captopril on Inducible Sustained Ventricular Tachycardia Two Weeks After Myocardial Infarction in the Pig. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 13, 186-191.	1.9	37
403	Captopril improves recovery of adenosine triphosphate during reperfusion of the ischemic isolated rat heart; a <sup>31</sup> -phosphorus nuclear magnetic resonance study. <i>Basic Research in Cardiology</i> , 1988, 83, 540-549.	5.9	7
404	Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. <i>American Journal of Medicine</i> , 1988, 84, 67-74.	1.5	43
405	Serum potassium values in relation to the use of diuretics in patients with unstable angina pectoris. <i>European Heart Journal</i> , 1988, 9, 795-799.	2.2	4
406	Captopril-Induced Increase in Coronary Flow. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 9, S31-S36.	1.9	42
407	Concentration-Dependent Protection by Captopril Against Myocardial Damage During Ischemia and Reperfusion in a Closed Chest Pig Model. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 9, S37-S42.	1.9	55
408	Effects of diltiazem on reperfusion-induced arrhythmias in vitro and in vivo. <i>Journal of Molecular and Cellular Cardiology</i> , 1986, 18, 1255-1266.	1.9	13
409	Sustained Protection by Iloprost of the Porcine Heart in the Acute and Chronic Phases of Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, 924-928.	1.9	29
410	Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion. <i>European Journal of Pharmacology</i> , 1984, 100, 113-117.	3.5	70
411	Improved functional recovery of the isolated rat heart after 24 hours of hypothermic arrest with a stable prostacyclin analogue (ZK 36 374). <i>Journal of Molecular and Cellular Cardiology</i> , 1983, 15, 789-792.	1.9	23